Intended Use

“MagQu” UCH-L1 IMR Reagent is used to quantitatively measure ubiquitin C-terminal hydrolase L1(UCH-L1) in human fluid specimen, such as plasma, serum or CSF.
Use “MagQu” UCH-L1 IMR Reagent only with the XacPro-S System (MagQu Co., Ltd.).

Introduction

Ubiquitin C-terminal hydrolase L1 (UCH-L1) is an extremely abundant deubiquitinating enzyme in brain, which involved in the elimination of misfolded proteins. UCH-L1 is not essential for neuronal development, but is necessary for maintenance of integrity. Recent studies have found an association between UCH-L1 dysfunction and neurodegenerative diseases. In previous studies, UCH-L1 expression was found to be decreased in patients with ischemic injury and Alzheimer's disease. It is possible that UCH-L1 increases free ubiquitin expression by promoting ubiquitination and accelerates lysosomal degradation of amyloid β-synuclein or α-synuclein, which tend to accumulate when they are reduced. Over-expression of UCH-L1 has also been shown in mouse models to effectively delay the progression of Alzheimer's disease. Thus, UCH-L1 may be a pre-dementia process with the potential to predict the onset of dementia. ^1,2,3

Principle of Test

“MagQu” UCH-L1 IMR Reagent is designed for rapid quantifying UCH-L1 by ImmunoMagnetic Reduction (IMR). We conjugate antibody on the surface of around 50 nm-in-diameter Fe₃O₄ magnetic particles. When the antibodies on the surface bind with UCH-L1, the magnetic particles form clusters. Therefore, the ac susceptibility (Xac) of magnetic particles would be reduced in the adding ac magnetic field. By measuring the reduction of Xac, UCH-L1 can be easily, rapidly and accurately quantified.⁴

References

1. Liu H, Povysheva N, Rose ME, et al. Role of UCHL1 in axonal injury and functional recovery after cerebral ischemia. Proc Natl Acad Sci U S A. 2019;116(10):4643-4650. 
2. Setsuie R, Wada K. The functions of UCH-L1 and its relation to neurodegenerative diseases. Neurochem Int. 2007;51(2-4):105-111. 
3. Liu MC, Akinyi L, Scharf D, et al. Ubiquitin C-terminal hydrolase-L1 as a biomarker for ischemic and traumatic brain injury in rats. Eur J Neurosci. 2010;31(4):722-732..
4. C.C. Yang, S.Y. Yang, C. S. Ho, et al., "Development of antibody functionalized magnetic nanoparticles for the immunoassay of carcinoembryonic antigen: a feasibility study for clinical use" J Nanobiotechnology. 12: 44. 2014.